Intern Emerg Med:缺血性卒中患者预防性应用抗生素,感染风险增加?

2016-05-31 phylis 译 MedSci原创

感染是导致急性缺血性卒中死亡的主要原因,但目前还不清楚是否预防性应用抗生素治疗可以改善预后。研究者旨在评估预防性抗生素治疗对感染的发生率和短期死亡率的影响。这是对18岁以上急性缺血性脑卒中患者进行的前瞻性多中心现实世界的分析,这些患者入院时美国国立卫生院卒中量表(NIHSS)> 11分。排除入院时或者入院前一个月有感染,入院时腋温超过37°C,有慢性炎症性疾病或应用糖皮质激素治疗的患者。11

感染是导致急性缺血性卒中死亡的主要原因,但目前还不清楚预防性应用抗生素治疗是否可以改善预后。研究者旨在评估预防性抗生素治疗对感染的发生率和短期死亡率的影响。

这是对18岁以上急性缺血性脑卒中患者进行的前瞻性多中心现实世界的分析,这些患者入院时美国国立卫生院卒中量表(NIHSS)> 11分。排除入院时或者入院前一个月有感染,入院时腋温超过37°C,有慢性炎症性疾病或应用糖皮质激素治疗的患者。

110例患者(44.5%为男性,80.2±6.8岁),其中31(28.2%)例接受预防性抗生素治疗,大多是头孢呋辛(n = 21)。预防性应用抗生素治疗的患者,51.4%发生感染,没有预防性抗生素治疗的患者,16.4%的患者发生感染。感染的独立预测因子是:入院时NIHSS评分(RR为1.16,95% CI 1.08-1.26)和预防性抗生素治疗(RR 5.84,95% CI 2.03-16.79)。预防性抗生素治疗和未进行预防性抗生素治疗的的患者,住院期间和出院时的死亡,或住院或随访期间患者死亡和出院后3个月内存活的患者的死亡没有差异。

严重急性缺血性卒中患者预防性应用抗生素,住院期间感染的风险增加,且不会影响短期死亡风险。

原始出处:

Tziomalos K, Ntaios G, et al. Prophylactic antibiotic treatment in severe acute ischemic stroke: the Antimicrobial chemopRrophylaxis for Ischemic STrokE In MaceDonIa-Thrace Study (ARISTEIDIS). Intern Emerg Med. 2016 May 23.


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2016-10-14 ylzr123

    赞一个!好文章拜读了,认真学习了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1806084, encodeId=5973180608462, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue May 02 21:27:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820130, encodeId=d141182013058, content=<a href='/topic/show?id=b20d1003117f' target=_blank style='color:#2F92EE;'>#预防性应用抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100311, encryptionId=b20d1003117f, topicName=预防性应用抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76fa353, createdName=tm10051981, createdTime=Thu Jul 14 13:27:00 CST 2016, time=2016-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892755, encodeId=4d071892e55f5, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Fri Nov 18 08:27:00 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148170, encodeId=69fc1481e096, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:06:30 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034755, encodeId=1dd12034e5589, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Wed Jul 13 00:27:00 CST 2016, time=2016-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010349, encodeId=52f1201034967, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Thu Mar 02 03:27:00 CST 2017, time=2017-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720112, encodeId=74be1e2011207, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Thu Jun 23 23:27:00 CST 2016, time=2016-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606931, encodeId=faf71606931d3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 01 23:27:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87891, encodeId=683b8e89113, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cache2.medsci.cn//images/medsci_toux.jpg, createdBy=7af91730839, createdName=足球疯子, createdTime=Tue May 31 21:00:00 CST 2016, time=2016-05-31, status=1, ipAttribution=)]
    2016-05-31 足球疯子

    不错的文章

    0

相关威廉亚洲官网

Stroke:住院感染是急性缺血性卒中的触发因素

急性脑缺血性卒中的诱因,可能包括感染,目前正在被研究其是否是具有心血管疾病(CVD)危险背景患者的触发因素,来自美国的研究人员假设,感染增加了急性卒中的风险,特别是那些低心血管疾病风险的患者。住院卒中和感染在社区动脉粥样硬化的风险(ARIC)队列中进行了鉴定。病例交叉设计和条件逻辑回归用于比较卒中患者的住院感染(卒中前14,30,42,和90天)和卒中前相应的卒中前1年和2年的控制时期的住院感染。

PLoS One: 比较中国人和白人脑出血和缺血性卒中的危险因素

背景:中国人群脑出血(ICH)在总卒中的比例较高。然而,原因并不能完全理解。方法:为了评估在中国与欧洲血统白人(ICH)和缺血性卒中(IS)发生的主要危险因素之间的差异,研究者系统的研究1990年后在中国与白人中进行的比较ICH和缺血性卒中风险因素之间研究。对每一个风险因素,将中国和白人分开研究,研究者计算了ICH vs 脑缺血,特定研究和随机效应合并的患病率和比值比(OR)。结果: 6项研究36

PLoS One:多学科参与的吞咽处理方法可降低急性卒中患者肺炎的发生

急性脑卒中患者易发生吞咽困难,其中许多患者发展为吸入性肺炎。利用每个专业的专业知识和技能,各专业人员间的团队合作可改善医疗质量。在研究者的医院,有一个多学科参与的吞咽团队组织。本研究比较团队组织处理前后对急性缺血性卒中患者肺炎发生的影响,证实团队组织处理对吞咽困难的影响。登记了2009年4月至2014年3月间,研究者医院收治的急性脑卒中患者。研究者分析了在团队治疗前(前期)团队治疗后(后期),卒中

J Stroke Cerebrovasc Dis:缺血性卒中患者,注意心脏功能检测!

背景:心脏骤停是急性缺血性脑卒中的严重并发症,但其发病及特点却不清楚。研究者研究了一个大型缺血性脑卒中住院人群,比较有无心脏骤停患者的特征。方法:来自加拿大的研究者研究来自安大略卒中登记处的缺血性卒中患者,这些患者2003年7月到2008年6月因缺血性卒中入住安大略11个三级医疗卒中中心,。多变量分析以确定心脏骤停独立的预测因素及相关的预后。建立校正生存曲线,确定心脏骤停和其他主要预后与30天和1

Lancet:TIA或缺血性卒中后预防复发性卒中,越早服用阿司匹林越好

临床试验表明阿司匹林可以降低复发性卒中13%的长期风险,因此阿司匹林被推荐用于短暂性脑缺血发作(TIA)或缺血性脑卒中的二级预防。然而,主要的卒中风险是只有在TIA和轻度缺血性脑卒中后的最初几天很高,观察研究表明在急性期的早期治疗比长期的试验有更多的好处。研究人员假设早期阿司匹林的短期效益被低估了。研究人员汇集了所有阿司匹林 vs 对照用于TIA或缺血性卒中二级预防随机试验的患者数据,研究人员研究

Ann Neurol:阿尔茨海默症和小血管缺血性卒中存在共同的遗传易感性

目的:越来越多的证据表明,阿尔茨海默氏症(AD)和缺血性卒中(IS)之间的流行病学和病理学相关。研究者调查的证据表明,这两种疾病存在共同的遗传因素。方法:应用METASTROKE +((15916例IS病例和68826例对照)和IGAP(17008例AD患者和37154名对照)研究中的数据,进行全基因组关联研究(GWAS),研究者评估AD和IS的相关性。研究者可获得基因水平的数据(4610例IS患